Therapy (HCV)

Clinical Data Reported for Investigational HCV Drug

Published in Hepatitis Weekly, November 22nd, 1999

VX-497 investigational drug appears to reduce liver inflammation in patients with hepatitis C virus (HCV) infection, according to results presented at the Annual Meeting of the American Association for the Study of Liver Diseases, held in Dallas, Texas, during November 1999.

VX-497 is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) being developed by Vertex Pharmaceuticals Inc.

Preliminary Phase II data for VX-497 indicate that the drug was well-tolerated and resulted in reduced levels of serum alanine aminotransferase (ALT), a marker of liver inflammation, in HCV patients treated for 28 days.

Vertex is now beginning...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1999-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry